Literature DB >> 14982790

Interactions between penicillin-binding proteins (PBPs) and two novel classes of PBP inhibitors, arylalkylidene rhodanines and arylalkylidene iminothiazolidin-4-ones.

Astrid Zervosen1, Wei-Ping Lu, Zhouliang Chen, Ronald E White, Thomas P Demuth, Jean-Marie Frère.   

Abstract

Several non-beta-lactam compounds were active against various gram-positive and gram-negative bacterial strains. The MICs of arylalkylidene rhodanines and arylalkylidene iminothiazolidin-4-ones were lower than those of ampicillin and cefotaxime for methicillin-resistant Staphylococcus aureus MI339 and vancomycin-resistant Enterococcus faecium EF12. Several compounds were found to inhibit the cell wall synthesis of S. aureus and the last two steps of peptidoglycan biosynthesis catalyzed by ether-treated cells of Escherichia coli or cell wall membrane preparations of Bacillus megaterium. The effects of the arylalkylidene rhodanines and arylalkylidene iminothiazolidin-4-one derivatives on E. coli PBP 3 and PBP 5, Streptococcus pneumoniae PBP 2xS (PBP 2x from a penicillin-sensitive strain) and PBP 2xR (PBP 2x from a penicillin-resistant strain), low-affinity PBP 2a of S. aureus, and the Actinomadura sp. strain R39 and Streptomyces sp. strain R61 DD-peptidases were studied. Some of the compounds exhibited inhibitory activities in the 10 to 100 microM concentration range. The inhibition of PBP 2xS by several of them appeared to be noncompetitive. The dissociation constant for the best inhibitor (Ki = 10 microM) was not influenced by the presence of the substrate.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14982790      PMCID: PMC353079          DOI: 10.1128/AAC.48.3.961-969.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

Review 1.  Towards new beta-lactam antibiotics.

Authors:  I Andersson; A C van Scheltinga; K Valegård
Journal:  Cell Mol Life Sci       Date:  2001-11       Impact factor: 9.261

2.  Development of a screening assay to measure the loss of antibacterial activity in the presence of proteins: its use in optimizing compound structure.

Authors:  Siddhartha Roychoudhury; Jessica L Brill; Wei-Ping Lu; Ronald E White; Zhuoliang Chen; Thomas P Demuth
Journal:  J Biomol Screen       Date:  2003-10

3.  Chromogenic depsipeptide substrates for beta-lactamases and penicillin-sensitive DD-peptidases.

Authors:  M Adam; C Damblon; B Plaitin; L Christiaens; J M Frère
Journal:  Biochem J       Date:  1990-09-01       Impact factor: 3.857

4.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

5.  Automated analysis of enzyme inactivation phenomena. Application to beta-lactamases and DD-peptidases.

Authors:  F De Meester; B Joris; G Reckinger; C Bellefroid-Bourguignon; J M Frère; S G Waley
Journal:  Biochem Pharmacol       Date:  1987-07-15       Impact factor: 5.858

6.  Antibacterial activity of synthetic analogues based on the disaccharide structure of moenomycin, an inhibitor of bacterial transglycosylase.

Authors:  E R Baizman; A A Branstrom; C B Longley; N Allanson; M J Sofia; D Gange; R C Goldman
Journal:  Microbiology       Date:  2000-12       Impact factor: 2.777

7.  DNA synthesis in nucleotide-permeable Escherichia coli cells. I. Preparation and properties of ether-treated cells.

Authors:  H P Vosberg; H Hoffmann-Berling
Journal:  J Mol Biol       Date:  1971-06-28       Impact factor: 5.469

8.  Interaction between the exocellular DD-carboxypeptidase-transpeptidase from Streptomyces R61, substrate and beta-lactam antibiotics. A choice of models.

Authors:  J M Frère; J M Ghuysen; H R Perkins
Journal:  Eur J Biochem       Date:  1975-09-15

Review 9.  Solving staphylococcal resistance to beta-lactams.

Authors:  Henry F Chambers
Journal:  Trends Microbiol       Date:  2003-04       Impact factor: 17.079

10.  The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors.

Authors:  E B Grant; D Guiadeen; E Z Baum; B D Foleno; H Jin; D A Montenegro; E A Nelson; K Bush; D J Hlasta
Journal:  Bioorg Med Chem Lett       Date:  2000-10-02       Impact factor: 2.823

View more
  17 in total

1.  One-pot synthesis of 5-arylidene-2-imino-4-thiazolidinones under microwave irradiation.

Authors:  Souad Kasmi-Mir; Ayada Djafri; Ludovic Paquin; Jack Hamelin; Mustapha Rahmouni
Journal:  Molecules       Date:  2006-08-10       Impact factor: 4.411

Review 2.  Resistance to antibiotics targeted to the bacterial cell wall.

Authors:  I Nikolaidis; S Favini-Stabile; A Dessen
Journal:  Protein Sci       Date:  2014-01-17       Impact factor: 6.725

3.  Rhodanine as a Potent Scaffold for the Development of Broad-Spectrum Metallo-β-lactamase Inhibitors.

Authors:  Yang Xiang; Cheng Chen; Wen-Ming Wang; Li-Wei Xu; Ke-Wu Yang; Peter Oelschlaeger; Yuan He
Journal:  ACS Med Chem Lett       Date:  2018-03-22       Impact factor: 4.345

4.  Rhodanine hydrolysis leads to potent thioenolate mediated metallo-β-lactamase inhibition.

Authors:  Jürgen Brem; Sander S van Berkel; WeiShen Aik; Anna M Rydzik; Matthew B Avison; Ilaria Pettinati; Klaus-Daniel Umland; Akane Kawamura; James Spencer; Timothy D W Claridge; Michael A McDonough; Christopher J Schofield
Journal:  Nat Chem       Date:  2014-11-17       Impact factor: 24.427

5.  Furanyl-rhodanines are unattractive drug candidates for development as inhibitors of bacterial RNA polymerase.

Authors:  Katherine R Mariner; Rachel Trowbridge; Anil K Agarwal; Keith Miller; Alex J O'Neill; Colin W G Fishwick; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

6.  Discovery and structure-activity relationship analysis of Staphylococcus aureus sortase A inhibitors.

Authors:  Nuttee Suree; Sung Wook Yi; William Thieu; Melanie Marohn; Robert Damoiseaux; Albert Chan; Michael E Jung; Robert T Clubb
Journal:  Bioorg Med Chem       Date:  2009-09-06       Impact factor: 3.641

7.  New noncovalent inhibitors of penicillin-binding proteins from penicillin-resistant bacteria.

Authors:  Samo Turk; Olivier Verlaine; Thomas Gerards; Matej Zivec; Jan Humljan; Izidor Sosič; Ana Amoroso; Astrid Zervosen; André Luxen; Bernard Joris; Stanislav Gobec
Journal:  PLoS One       Date:  2011-05-09       Impact factor: 3.240

Review 8.  Recent pharmacological developments on rhodanines and 2,4-thiazolidinediones.

Authors:  Ravinder Singh Bhatti; Sakshi Shah; Pawan Krishan; Jagir S Sandhu
Journal:  Int J Med Chem       Date:  2013-05-02

9.  Discovery of Pyrrolidine-2,3-diones as Novel Inhibitors of P. aeruginosa PBP3.

Authors:  Arancha López-Pérez; Stefan Freischem; Immanuel Grimm; Oliver Weiergräber; Andrew J Dingley; María Pascual López-Alberca; Herbert Waldmann; Waldemar Vollmer; Kamal Kumar; Cuong Vuong
Journal:  Antibiotics (Basel)       Date:  2021-05-04

10.  High-throughput screening for novel inhibitors of Neisseria gonorrhoeae penicillin-binding protein 2.

Authors:  Alena Fedarovich; Kevin A Djordjevic; Shauna M Swanson; Yuri K Peterson; Robert A Nicholas; Christopher Davies
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.